Table 5. Most frequent investigator-reported treatment-emergent drug-related adverse events reported in the ITT (safety) population (≥2% of patients in either treatment group).

Preferred term, n (%)	CDA (N = 914)	AL (N = 458)
Reticulocyte count decreased	79 (9)	44 (10)
Anemia	24 (3)	9 (2)
Hemoglobin decreased	24 (3)	7 (2)
Vomiting	14 (2)	4 (<1)
Thrombocytopenia	15 (2)	3 (<1)
Patients with at least one drug-related adverse event	184 (20)	86 (19)